BPC-157 (10mg) + TB500 (10mg)
Contents
- Quickstart Highlights
- Dosing & Reconstitution Guide
- Standard / Gradual Titration (3 mL = ~3.33 mg/mL)
- Reconstitution Steps
- Supplies Needed
- Protocol Overview
- Dosing Protocol
- Storage Instructions
- Important Notes
- How This Works
- Potential Benefits & Side Effects
- Lifestyle Factors
- Injection Technique
- Recommended Source
- Important Note
- References
Quickstart Highlights
This protocol covers the use of a regenerative peptide blend combining BPC-157 (Body Protection Compound-157) and TB-500 (Thymosin Beta-4 fragment).
- BPC-157 is a 15-amino-acid peptide derived from human gastric juice, known for cytoprotective, wound-healing, and tissue repair properties.
- TB-500 is a 43-amino-acid peptide that promotes cell migration, angiogenesis, and tissue regeneration.
This guide presents daily subcutaneous administration with practical dilutions for precise insulin-syringe measurements.
Reconstitution & Concentration
- Add 3.0 mL bacteriostatic water to a 10 mg peptide blend vial.
- Total concentration: ~3.33 mg/mL (1.67 mg/mL of each peptide).
- Typical daily dose: 600–1000 mcg total (300–500 mcg of each peptide).
- Measurement tip: 1 unit on a U-100 insulin syringe = 0.01 mL ≈ 33.3 mcg total blend.
- Storage: Lyophilized vials freeze at −20 °C; reconstituted solution refrigerate at 2–8 °C. Avoid freeze-thaw cycles.
Dosing & Reconstitution Guide
Educational guide for reconstitution and daily dosing
Standard / Gradual Titration (3 mL = ~3.33 mg/mL) Subcutaneous injection, once daily.
| Phase / Week | Daily Dose (Total Blend) | Each Peptide (mcg) | Units (mL) |
|---|---|---|---|
| Weeks 1–2 (Aggressive Load) | 1000 mcg | 500 mcg BPC + 500 mcg TB-500 | 30 units (0.30 mL) |
| Weeks 3–4 (High Load) | 800 mcg | 400 mcg BPC + 400 mcg TB-500 | 24 units (0.24 mL) |
| Weeks 5–8 (Maintenance) | 600 mcg | 300 mcg BPC + 300 mcg TB-500 | 18 units (0.18 mL) |
Frequency: Inject once daily subcutaneously. This schedule uses 3.0 mL dilution to keep per-injection volumes ≥18 units for accurate measurement. Rotate injection sites systematically
Reconstitution Steps
- Draw 3.0 mL bacteriostatic water with a sterile syringe.
- Inject slowly along the vial wall; avoid foaming.
- Gently swirl or roll until fully dissolved; do not shake.
- Label with reconstitution date and refrigerate at 2–8 °C, protected from light.
- Use within 28 days.
Important: This guide is for educational purposes only and is not medical advice. For research use only. Not for human consumption.
Advanced / Aggressive Approach (Acute Injury Support)
For acute tissue repair, a higher initial loading phase may be used with caution.
| Phase / Week | Daily Dose (Total Blend) | Each Peptide (mcg) | Units (mL) |
|---|---|---|---|
| Weeks 1–2 (Aggressive Load) | 1000 mcg | 500 mcg BPC + 500 mcg TB-500 | 30 units (0.30 mL) |
| Weeks 3–4 (High Load) | 800 mcg | 400 mcg BPC + 400 mcg TB-500 | 24 units (0.24 mL) |
| Weeks 5–8 (Maintenance) | 600 mcg | 300 mcg BPC + 300 mcg TB-500 | 18 units (0.18 mL) |
Note: Limited human data suggests that combining BPC-157 and TB-500 at higher doses may improve outcomes in joint-related conditions. In one small case series, higher combined doses (4 mg BPC-157 + 6 mg TB-500 administered intra-articularly) showed better results compared to lower-dose approaches.
However, most standard protocols using subcutaneous administration follow the lower dosing ranges outlined above. Treatment is typically conducted for 8–12 weeks, after which a break or reassessment period is recommended to evaluate response and progress.
Supplies Needed
- Peptide Vials (10 mg blend each):
- 8 weeks: 4 vials
- 12 weeks: 6 vials
- 16 weeks: 8 vials
- Insulin Syringes (U-100):
- Daily injections → 7 syringes/week
- 8 weeks: 56 syringes
- 12 weeks: 84 syringes
- 16 weeks: 112 syringes
- Bacteriostatic Water (10 mL bottles):
- 3 mL per vial for reconstitution
- 8 weeks: 12 mL → 2 × 10 mL bottles
- 12 weeks: 18 mL → 2 × 10 mL bottles
- 16 weeks: 24 mL → 3 × 10 mL bottles
- Alcohol Swabs: One for vial, one for injection site daily.
- 8 weeks: 112 swabs → 2 × 100-count boxes
- 12 weeks: 168 swabs → 2 × 100-count boxes
- 16 weeks: 224 swabs → 3 × 100-count boxes
Protocol Overview
- Goal: Support tissue repair, wound healing, and recovery from musculoskeletal injuries.
- Schedule: Daily subcutaneous injections for 8–12 weeks; optional extension to 16 weeks.
- Dose Range: 600–1000 mcg total blend daily (300–500 mcg of each peptide).
- Reconstitution: 3 mL per 10 mg vial (~3.33 mg/mL).
- Storage: Lyophilized frozen; reconstituted refrigerated; avoid repeated freeze-thaw cycles.
Dosing Protocol
A structured daily approach with gradual adjustments to support tolerance and effectiveness:
- Weeks 1–2 (Initiation): 600 mcg total per day (300 mcg of each peptide).
- Weeks 3–4 (Loading Phase): Increase to 800 mcg total per day (400 mcg of each peptide).
- Weeks 5–8+ (Maintenance): Reduce back to 600 mcg total per day (300 mcg of each peptide).
Frequency: Administer once daily via subcutaneous injection.
Cycle Duration: Typically 8–12 weeks, with the option to extend up to 16 weeks depending on response and goals.
Storage Instructions
Proper storage is essential to maintain the quality and effectiveness of the peptide.
- Lyophilized (unmixed): Keep refrigerated at 2–8°C (35.6–46.4°F). Some newer formulations (such as Egrifta SV) may remain stable at room temperature (20–25°C / 68–77°F) before mixing.
- After reconstitution (with bacteriostatic water): Store in the refrigerator at 2–8°C and use within 7 days.
- After reconstitution (with sterile water): Use immediately and discard any remaining solution.
- Avoid freezing the mixed solution and do not subject it to repeated freeze–thaw cycles.
Important Notes
- These peptides are for research purposes and not approved for routine human use.
- Use a new sterile syringe for each injection.
- Document daily dose and injection site to maintain consistency.
How This Works
BPC-157 is a stable peptide composed of 15 amino acids that supports tissue repair through multiple pathways. It promotes angiogenesis (formation of new blood vessels), helps regulate nitric oxide activity, and provides broad protective effects across the gastrointestinal system, muscles, and nervous tissue. Preclinical research suggests it remains effective even at very low doses, with no significant toxicity observed in animal studies.
TB-500 (Thymosin Beta-4) is a peptide involved in cell movement and regeneration. It works by supporting cell migration, enhancing wound healing, and reducing inflammation. It has shown good tolerability in both animal and early-stage human research, even at higher dose ranges.
When used together, these peptides may offer complementary benefits for tissue repair and recovery. BPC-157 contributes protective and anti-inflammatory effects, while TB-500 enhances cell migration and blood vessel formation, potentially improving overall healing outcomes.
Potential Benefits & Considerations
- Accelerated healing of tendons, ligaments, muscles, and soft tissue injuries.
- Gastroprotective and anti-inflammatory properties (BPC-157).
- May reduce scarring and improve tissue regeneration (TB-500).
- Generally well-tolerated; occasional mild injection-site reactions.
Lifestyle Factors
For optimal outcomes, consider combining with supportive habits:
- Maintain adequate protein intake (1.6–2.2 g/kg body weight).
- Follow rehabilitation or physical therapy protocols.
- Ensure 7–9 hours of sleep for optimal tissue recovery.
- Support recovery with proper nutrition and stress management.
Injection Technique
- Clean vial stopper and skin with alcohol; allow to dry.
- Pinch a skinfold and insert the needle 45–90° into subcutaneous tissue.
- Do not aspirate; inject slowly and steadily.
- Rotate injection sites systematically: abdomen (≥2 inches from navel), thighs, upper arms, flank.
- Apply gentle pressure; do not rub.
Recommended Source
We recommend Fit Aminos for high-purity research peptide products.
Why Fit Aminos?
- High-purity, lab-tested peptide batches with quality verification.
- Consistent handling and preparation processes designed to support reliable research protocols.
- Transparent sourcing and dependable fulfillment for research-grade compounds.
Important Note
This content is intended for educational and research purposes only and does not constitute medical advice, diagnosis, or treatment.
BPC-157 (10mg) + TB500 (10mg) remains an investigational peptide with limited human clinical data. For research use only. Not for human consumption.
References
PubMed
— Preclinical safety evaluation of body protective compound-157, a potential drug for treating various wounds
Current Pharmaceutical Design (PubMed)
— Stable gastric pentadecapeptide BPC-157: novel therapy in gastrointestinal tract
PMC
— Utilizing developmentally essential secreted peptides such as Thymosin Beta-4 for regenerative therapies
Annals of the New York Academy of Sciences (PubMed)
— Thymosin beta 4 and wound healing: new ideas